← Back to Clinical Trials
Recruiting NCT06953622

NCT06953622 Establishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06953622
Status Recruiting
Phase
Sponsor Peking University Third Hospital
Condition Migraine
Study Type OBSERVATIONAL
Enrollment 330 participants
Start Date 2024-01-01
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Conservative treatmentAntipaletet drugPatent Foramen Ovale Closure

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 330 participants in total. It began in 2024-01-01 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To establish a headache center in China that combines clinical, imaging and laboratory examinations, explore the feasible treatment options for migraine combined with patent foramen ovale, and search for the possible influencing factors, construct models that influence prognosis.

Eligibility Criteria

Inclusion Criteria: * Meet the diagnostic criteria for migraine in the International Classification of Headache (ICHD-3); * Confirmation of patent foramen ovale through transthoracic echocardiography(TTE) or transesophageal echocardiography(TEE)/right heart contrast echocardiography * Agree to participate in the study and sign the informed consent form. Exclusion Criteria: * Can not sign the informed consent form or cooperate with follow-up.

Contact & Investigator

Central Contact

Yu Fu

✉ lilac_fu@126.com

📞 13671185050

Frequently Asked Questions

Who can join the NCT06953622 clinical trial?

This trial is open to participants of all sexes, studying Migraine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06953622 currently recruiting?

Yes, NCT06953622 is actively recruiting participants. Contact the research team at lilac_fu@126.com for enrollment information.

Where is the NCT06953622 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT06953622 clinical trial?

NCT06953622 is sponsored by Peking University Third Hospital. The trial plans to enroll 330 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology